COVID-19

Center for Medicare Services Established National Pricing of AmnioWrap2™ in All MAC Regions

Pricing Provides AmnioWrap2™ Reimbursement in All MAC Regions We Manufacture Products That Change Lives We Manufacture Products That Change Lives POMPANO…

5 months ago

U.S. FDA Approves MedMira’s Advanced Reveal G4 Rapid HIV-1/2 Antibody Test

HALIFAX, NOVA SCOTIA / ACCESSWIRE / December 13, 2023 / MedMira Inc. (MedMira) (TSXV:MIR) proudly announces today the successful attainment…

5 months ago

Metrodora Institute Appoints Dr. Brent P. Goodman, MD, as Chief Medical Officer

Metrodora Institute Appoints Dr. Brent P. Goodman, MD, as Chief Medical Officer to Propel Innovations in Complex Multisystem Disorder CareSALT…

5 months ago

Metrodora Institute Appoints Dr. Brent P. Goodman, MD, as Chief Medical Officer

Metrodora Institute Appoints Dr. Brent P. Goodman, MD, as Chief Medical Officer to Propel Innovations in Complex Multisystem Disorder CareSALT…

5 months ago

BioStem Technologies Bolsters Leadership with Appointment of Thomas Dugan to Board of Directors

POMPANO BEACH, Fla., Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC:BSEM), a leading regenerative medicine company focused on…

5 months ago

CloudMD Reports Robust Results in Restated, Q3 2023 Financial Results

Reports filing of Restated Q3 2023 Financial Statements and Restated 2022 Audited Consolidated Financial StatementsThird Quarter HighlightsNet Loss of $5.4…

5 months ago

Preventogen is a New Tool in the Fight Against Antibiotic-Resistant Infections Caused by Superbugs, a Leading Cause of Death Worldwide

Preventogen's FDA-Cleared Microbicidal Liquid Polymer Ensures the Eradication of These Dangerous Pathogens on Contact While Forming a More Effective and…

5 months ago

Ainos, Inc. Announces Stock Consolidation

SAN DIEGO, CA / ACCESSWIRE / December 12, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos," or the "Company"), a diversified…

5 months ago

ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs

Following the successful TREK-AD Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, process is underway to identify potential partners.…

5 months ago